The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …

Over the past decade, rapid advances in genomics, proteomics and functional genomics
technologies that enable in-depth interrogation of cancer genomes and proteomes and high …

DNA replication in cancer cells is accompanied by stalling and collapse of the replication
fork and signalling in response to DNA damage and/or premature mitosis; these processes …

Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that
shows great promise for tumour selectivity. Key components of the DDR are the ataxia …

Advances in our understanding of the intricate molecular mechanisms for transformation of a
normal cell to a cancer cell, and the aberrant control of complementary pathways, have …

RNA interference (RNAi) is an effective tool for genome-scale, high-throughput analysis of
gene function. In the past five years, a number of genome-scale RNAi high-throughput …

Neuroblastoma is a childhood cancer that is often fatal despite intense multimodality
therapy. In an effort to identify therapeutic targets for this disease, we performed a …

The rapid development of new therapeutic agents that target specific molecular pathways
involved in tumour cell proliferation provides an unprecedented opportunity to achieve a …

G-quadruplexes (G4) are alternative nucleic acid structures involved in transcription,
translation and replication. Aberrant G4 formation and stabilisation is linked to genome …

The ataxia telangiectasia mutated serine/threonine kinase (ATM)/checkpoint kinase 2
(CHEK2, best known as CHK2) and the ATM and Rad3-related serine/threonine kinase …